Recruitment

Recruitment Status
Unknown status

Inclusion Criterias

Willingness to not use other forms of hormonal treatment.
Women without reproductive system infection complications.
Healthy women,aged 20-35 years who wish to use a contraceptive.
...
Willingness to not use other forms of hormonal treatment.
Women without reproductive system infection complications.
Healthy women,aged 20-35 years who wish to use a contraceptive.
Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).
Signed informed consent prior to entry into the trial.

Exclusion Criterias

Any contraindication to the use of oral contraceptives.
Vascular, metabolic, hepatic, renal, oncologic and other diseases.
Any contraindication to the use of oral contraceptives.
Vascular, metabolic, hepatic, renal, oncologic and other diseases.

Summary

Conditions
Oral Contraceptive
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 20 years and 35 years
Gender
Only females

Inclusion Criterias

Willingness to not use other forms of hormonal treatment.
Women without reproductive system infection complications.
Healthy women,aged 20-35 years who wish to use a contraceptive.
...
Willingness to not use other forms of hormonal treatment.
Women without reproductive system infection complications.
Healthy women,aged 20-35 years who wish to use a contraceptive.
Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).
Signed informed consent prior to entry into the trial.

Exclusion Criterias

Any contraindication to the use of oral contraceptives.
Vascular, metabolic, hepatic, renal, oncologic and other diseases.
Any contraindication to the use of oral contraceptives.
Vascular, metabolic, hepatic, renal, oncologic and other diseases.

Locations

Taizhou, Zhejiang, 317000
Shantou, Guangdong, 515041
Zhongshan, Guangdong, 528403
Changsha, Hunan, 410013
Beijing, Beijing, 100730
...
Taizhou, Zhejiang, 317000
Shantou, Guangdong, 515041
Zhongshan, Guangdong, 528403
Changsha, Hunan, 410013
Beijing, Beijing, 100730
Nanjing, Jiangsu, 210009
Wulumuqi, Xinjiang, 830054
Chongqing, Chongqing, 400042
Chongqing, Chongqing, 400010
Yangzhou, Jiangsu, 225009
Guiyang, Guizhou, 550000
Tianjin, Tianjin, 300211
Shanghai, Shanghai, 200021
Nanjing, Jiangsu, 210036
Wuhan, Hubei, 430030
Xi'an, Shanxi, 710061
Taiyuan, Shanxi, 030013
Guangzhou, Guangdong, 510120
Changde, Hunan, 415003
Beijing, Beijing, 100039
Guiyang, Guizhou, 550002

Tracking Information

NCT #
NCT02021097
Collaborators
Not Provided
Investigators
  • Principal Investigator: Chengliang Xiong, Dr Family Planning Research Institute of TJMC,HUST
  • Chengliang Xiong, Dr Family Planning Research Institute of TJMC,HUST